Trial ID or NCT#

NCT02927964

Status

recruiting iconRECRUITING

Purpose

This phase Ib/II trial studies the side effects and best dose of toll-like receptor 9 (TLR9) agonist SD-101 when given together with ibrutinib and radiation therapy and to see how well they work in treating patients with Low Grade Follicular Lymphoma, Marginal Zone Lymphoma, or Mantle Cell Lymphoma that has come back after a period of improvement or no longer responds to treatment. Immunostimulants such as TLR9 agonist SD-101 may increase the ability of the immune system to fight infection and disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving TLR9 agonist SD-101 with ibrutinib and radiation therapy may induce an immune response and prolong anti-tumor response.

Official Title

Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Ronald Levy, MD
Ronald Levy, MD
Medical oncologist, Lymphoma specialist
Robert K. and Helen K. Summy Professor in the School of Medicine
Michael Khodadoust
Michael Khodadoust
Medical oncologist, Lymphoma specialist, Cutaneous oncology specialist, Hematologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Tanaya Shree
Instructor, Medicine - Oncology

Contact us to find out if this trial is right for you.

CONTACT

Alyssa Michelle Kanegai
(650) 736-1596